Novo Nordisk A/S (NVO)
47.08
+0.31
(+0.66%)
USD |
NYSE |
Sep 03, 16:00
47.35
+0.27
(+0.57%)
After-Hours: 20:00
Novo Nordisk Research and Development Expense (TTM) : 8.086B for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 8.086B |
| March 31, 2026 | 8.079B |
| December 31, 2025 | 7.923B |
| September 30, 2025 | 7.614B |
| June 30, 2025 | 6.601B |
| March 31, 2025 | 7.158B |
| December 31, 2024 | 6.957B |
| September 30, 2024 | 6.491B |
| June 30, 2024 | 6.280B |
| March 31, 2024 | 4.989B |
| December 31, 2023 | 4.706B |
| September 30, 2023 | 4.306B |
| June 30, 2023 | 3.882B |
| March 31, 2023 | 3.574B |
| December 31, 2022 | 3.389B |
| September 30, 2022 | 3.146B |
| June 30, 2022 | 3.057B |
| March 31, 2022 | 2.964B |
| December 31, 2021 | 2.818B |
| September 30, 2021 | 2.670B |
| June 30, 2021 | 2.610B |
| March 31, 2021 | 2.457B |
| December 31, 2020 | 2.375B |
| September 30, 2020 | 2.307B |
| June 30, 2020 | 2.229B |
| Date | Value |
|---|---|
| March 31, 2020 | 2.278B |
| December 31, 2019 | 2.129B |
| September 30, 2019 | 2.174B |
| June 30, 2019 | 2.206B |
| March 31, 2019 | 2.198B |
| December 31, 2018 | 2.338B |
| September 30, 2018 | 2.274B |
| June 30, 2018 | 2.231B |
| March 31, 2018 | 2.209B |
| December 31, 2017 | 2.133B |
| September 30, 2017 | 2.150B |
| June 30, 2017 | 2.143B |
| March 31, 2017 | 2.143B |
| December 31, 2016 | 2.160B |
| September 30, 2016 | 2.104B |
| June 30, 2016 | 2.076B |
| March 31, 2016 | 2.020B |
| December 31, 2015 | 2.022B |
| September 30, 2015 | 2.079B |
| June 30, 2015 | 2.239B |
| March 31, 2015 | 2.354B |
| December 31, 2014 | 2.445B |
| September 30, 2014 | 2.447B |
| June 30, 2014 | 2.294B |
| March 31, 2014 | 2.204B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| AstraZeneca PLC | 14.21B |
| Johnson & Johnson | 15.06B |
| Eli Lilly & Co. | 14.60B |
| Merck & Co., Inc. | 27.26B |
| Novartis AG | 11.26B |